I
ncidental adrenal masses are being discovered with greater frequency because of the increased use and improved quality of cross-sectional imaging [1] . These lesions, known as "adrenal incidentalomas" (AIs), refer to unsuspected adrenal masses 1 cm or larger that are detected on imaging studies, excluding studies of patients who are being evaluated for cancer [2] .
AIs present diagnostic challenges for both radiologists and referring clinicians, particularly when the initial imaging characteristics are nonspecific. Although most AIs are benign, some may prove to be hormone secreting, malignant, or both. The American College of Radiology (ACR) [2, 3] , the American Association of Clinical Endocrinologists, the American Association of Endocrine Surgeons [4] , and the National Institutes of Health (NIH) [5] have independently developed guidance in the workup of AIs.
In this article, we provide a brief review of adrenal mass imaging and a discussion of the primary imaging and clinical guidelines, including their key similarities and differences. We suggest an alternative approach to the imaging and clinical workup of AIs that combines the imaging expertise of the ACR and the clinical expertise of the American Association of Clinical Endocrinologists, the American Association of Endocrine Surgeons, and the NIH. Finally, we provide sample radiology report dictations that have been developed at our institution to provide consistency in follow-up recommendations for AIs.
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of images at 70-80 seconds and at 15 minutes after contrast administration, uses characteristics of contrast washout to differentiate adenomas from nonadenomas [1, 15, 16] (Figs. 1D-1F ). This is particularly helpful for identifying lipid-poor adrenal adenomas, which can appear similar to nonadenomas on unenhanced CT and chemical selective MRI. Adenomas display rapid contrast washout at 15 minutes, whereas nonadenomas typically undergo slow contrast washout [15] [16] [17] [18] .
Myelolipomas contain macroscopic fat, which is characterized by attenuation of less than −20 HU on CT and signal dropout on fat-suppressed MRI sequences [19] [20] [21] (Fig.  2) . Macroscopic fat rarely can be seen in adrenal adenomas, adrenocortical carcinomas (ACCs), and pheochromocytomas, and large myelolipomas may be difficult to distinguish from liposarcomas [19] [20] [21] .
In the acute stage, adrenal hemorrhage appears as hyperattenuating on CT, with attenuation usually measuring 50-90 HU [22, 23] . Although this attenuation may be diagnostic on unenhanced CT, it is indistinguishable from tumor on contrast-enhanced CT (CECT) (Fig. 3A) and therefore may require a followup CT examination in 1-2 months to confirm decreased hematoma size and attenuation [24] . MRI can also be used to confirm adrenal hemorrhage, although its appearance on MRI depends on the age of the hemorrhage (Fig. 3B) . Adrenal cysts are rare and can be distinguished from cystic malignancy on CT and MRI if they display no enhancement, nearwater attenuation or signal, wall thickness of less than 3 mm, and size no greater than 5-6 cm [25] .
Incidental adrenal masses that have nonspecific features on CT and MRI, including metastases, pheochromocytomas, and adrenal cortical carcinomas, cannot be reliably characterized with the use of imaging alone. The imaging features of metastases to the adrenal glands are generally nonspecific and include necrosis (Fig. 4) , heterogeneity, density of 10 HU or more on unenhanced CT, slow contrast washout on adrenal protocol CT, no
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Fig. 1-Three patients with adrenal adenoma.
A, 33-year-old woman with right adrenal mass incidentally discovered on unenhanced CT performed for flank pain. Mean attenuation of −5.92 HU is diagnostic of benign adenoma or cyst. Circle denotes ROI. B and C, 66-year-old woman who underwent surveillance MRI for liver disease. In-phase (B) and opposed-phase (C) MR images show right adrenal mass (arrow). Opposed-phase image (C) shows decreased signal intensity, which is diagnostic of lipid-rich adenoma. D-F, 53-year-old man with hyperaldosteronism and refractory hypertension. Adrenal protocol CT images include unenhanced CT image (D) (mean attenuation, 21.69 HU), portal venous phase CT image (E) (mean attenuation, 59.58 HU), and 15-minute delayed CT image (F) (mean attenuation, 32.17 HU), all of which were diagnostic of lipidpoor adenoma. Absolute percentage washout was 72%, and relative percentage washout was 46%. Circles denotes ROIs.
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signal dropout on chemical selective MRI, and signal hyperintensity on T2-weighted MR images [26] . 18 F-FDG PET frequently is performed during the workup of malignancy and is a very accurate method for differentiating benign from malignant adrenal masses that are larger than 1 cm [27] . Pheochromocytomas typically are large vascular tumors that display avid enhancement on CT and MRI [28, 29] . On adrenal protocol CT, pheochromocytomas usually display slow contrast washout, although, on occasion, they may [28, 29] . Although they typically are described as having marked signal hyperintensity on T2-weighted MRI, approximately 35% of pheochromocytomas may have signal hypointensity [30] . Metaiodobenzylguanidine scintigraphy is highly specific for pheochromocytomas and paraganglioma and usually is performed either when there is biochemical evidence of pheochromocytoma without imaging evidence or when searching for metastases [31] . Biochemical testing typically is used to confirm the diagnosis of pheochromocytoma, and cross-sectional imaging is sufficient for tumor localization [31] (Fig. 5) . Primary ACC is rare and often is large (> 6 cm) at the time of detection [32] (Figs. 6A and 6B). Imaging characteristics are nonspecific, although heterogeneity, necrosis, and vascular invasion are commonly seen, and calcifications are present in 30% of ACCs [32] .
Imaging and Clinical Guidelines
The accurate characterization of AIs can be a complex process because of the variety of imaging options available, the frequency of adrenal masses with indeterminate imaging features, and the possibility of hormonal dysfunction in both benign and malignant masses. In an effort to simplify the process, several guidelines have been developed, including those put forth by the ACR in 2010 [2] and 2012 [3] , those from the American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons [4] , and those developed by the NIH [5] . Although these guidelines are each thorough and well designed, they are different in perspective and, thus, emphasis. These differences in perspective and emphasis have led to variations in the guidelines, particularly in areas that are subject to expert or consensus opinion because of the lack of large long-term studies.
Imaging Guidelines
The major radiologic guidelines include the 2010 white paper of the ACR Incidental Findings Committee [2] and the ACR appropriateness criteria for the imaging evaluation of incidentally discovered adrenal masses, which were published in 2012 [3] . The ACR white paper includes a sample flowchart for the imaging evaluation of AIs ( Fig. 7) , with the goal of offering the most efficient and effective diagnostic approach to distinguishing benign from malignant masses.
Clinical Guidelines
The major clinical guidelines include the 2009 practice guidelines of the American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons [4] , the 2002 NIH Consensus Statement [5] , and the expert opinion of Young [33] published in the New England Journal of Medicine in 2007. Although mindful of the important role of imaging in lesion characterization, these clinical guidelines place a greater focus on biochemical analysis as a means of follow-up of AIs (Table 1) .
Analysis of Imaging and Clinical Guideline Objectives
The first objective of both the radiologic and clinical algorithms is to distinguish benign from malignant adrenal masses. This aspect can be quite challenging because of the rarity of adrenal malignancy and the overlap in imaging features between benign and malignant masses. The majority of AIs are benign in patients with no previously known malignancy [34] [35] [36] [37] [38] . Even in patients with a primary nonadrenal malignancy known to be associated with a high frequency of adrenal metastases, only 50% of AIs are caused by metastatic disease [34] . Primary ACC, although devastating, occurs with a frequency of 1-2 cases per million population [38, 39] . Observation of indeterminate radiologic features at initial diagnosis further complicates the imaging workup of AIs. Approximately 30% of adenomas, which are the most common AIs, are lipid poor and cannot be distinguished from malignancy on unenhanced CT [4, 5] . Routine CECT cannot distinguish adenomas from nonadenomas because of the overlap in attenuation values [15] . It is critically important to use imaging appropriately, to accurately classify AIs with the use of the fewest number of imaging studies and the lowest amount of ionizing radiation. The ACR white paper algorithm and the ACR appropriateness criteria use the available imaging tools to provide concise evidence-based guidelines for differentiating benign adrenal masses from malignant or indeterminate masses.
The role of percutaneous biopsy in differentiating benign from malignant masses differs in the radiologic [2, 3] and clinical [4, 5, 33] guidelines. The ACR contends that biopsy may be performed for indeterminate mass- 3 Noncontrast CT or MRI may alternatively be used to characterize 1-to 4-cm masses in patients with a history of cancer and no prior imaging. 4 A 1-mg dexamethasone suppression test (or assessment of 24-hour urinary cortisol level), assessment of plasma (or urine) level of metanephrines, and aldosterone-to-renin activity ratio (if patient has hypertension or a low potassium level). 5 Some experts recommend that masses ≥ 4 cm be resected even if nonfunctional, because of increased risk of adrenal cancer, although these guidelines do not distinguish masses with features diagnostic of adenoma [4, 33] . It may be more appropriate for nonfunctional masses ≥ 4 cm with features diagnostic of adenoma to be followed with imaging and with hormonal evaluation [5] or with hormonal evaluation only. es that measure 1-4 cm and that have either grown or have retained their indeterminate status after all imaging options are exhausted, in addition to masses larger than 4 cm that occur in patients with a history of malignancy [2, 3] . Conversely, there is general agreement in the endocrinology literature that biopsy should be performed only if knowledge of metastatic disease from a known primary malignancy will affect further therapy. Biopsy cannot reliably distinguish adrenal adenoma from ACC and may be harmful because of the risk of tumor seeding [4, 5, 33, 39] .
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The second objective of these diagnostic algorithms is to determine the functional status of AIs. Although most patients with AIs have nonfunctioning adenomas (80%), 5-10% have subclinical or early Cushing syndrome, 5% have pheochromocytoma, and 1% have aldosteronoma [33, 36, 37] . The ACR algorithm considers biochemical (hormonal) evaluation, but the document states that routine hormonal evaluation of all incidentalomas "would be costly and is not routinely performed by many physicians" [2] . Furthermore, biochemical evaluation should be considered only "if there are clinical signs or symptoms of adrenal hyperfunction" [2] . This view is contrary to the preponderance of clinical recommendations in the endocrine literature [4, 5, 33, 36, 37, 40] .
With the increasing use of imaging, many pheochromocytomas are being detected as AIs rather than as part of a planned evaluation. As many as 12.5% of patients with pheochromocytomas are normotensive, and only 10% present with the clinical triad of sweating, headaches, and palpitations [36] . In one series, adrenal pheochromocytomas were identified as AIs in 19 of 33 patients (58%), and only 10 of these 19 patients had hypertension [41] . However, even clinically silent pheochromocytomas can be lethal [4, 5, 33] . All patients with suspected pheochromocytomas, even those who are normotensive, should be adequately prepared to undergo surgery by receiving α-adrenoceptor blockade or calcium channel blockers to prevent a hypertensive crisis [4] . Because pheochromocytomas have nonspecific features on imaging, and because clinical expertise in diagnosing pheochromocytomas may vary, it has been suggested that all adrenal masses be screened for catecholamine excess [4, 5, 33] . Plasma metanephrines have similar sensitivity and specificity for pheochromocytoma as urine fractionated metanephrines and may be considered as the first screening test [42] .
Subtle, or subclinical, Cushing syndrome refers to the autonomous secretion of cortisol in patients who lack the typical signs and symptoms of hypercortisolism. The prevalence of subclinical Cushing syndrome may range from 5% to 24%, depending on the diagnostic criteria for testing [36, 37] , although the true prevalence is likely to be at the lower end of this range [38] . Subclinical cortisol secretion has been associated with hypertension, obesity, diabetes, osteoporosis, and an increased risk of cardiovascular events [33, 43] . There is no general consensus on which diagnostic test is most suitable for the diagnosis of subclinical Cushing syndrome. An overnight 1-mg dexamethasone suppression test for which the posttest serum cortisol level is abnormal (> 5 μg/dL) and the plasma level of adrenocorticotropic hormone suppressed is more sensitive than a 24-hour urinary free cortisol test but is less specific [37, 44] .
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Aldosteronomas account for 1% of AIs and have been associated with an increased risk of cardiovascular disease [33] . Hyperaldosteronism, which may occur in as many as 16% of individuals with resistant hypertension, warrants workup to decide whether treatment should involve a mineralocorticoid receptor blockade or resection of a hyperfunctioning adenoma [33, 45] . Hypertension and a low or low-normal serum potassium level may be insufficient screening criteria for hyperaldosteronism [33] . For patients with hypertension and an AI, an appropriate screening test is a random aldosterone-to-renin activity ratio that is greater than 30 [45] .
The third objective of these guidelines is appropriate imaging follow-up of AIs with benign characteristics. Consensus guidelines in the endocrinology literature recommend extended imaging follow-up for AIs smaller than 4 cm, even if they are benign and nonfunctioning [4, 5, 33, 40, 43, 46, 47] (Table 1) . However, there is a lack of evidence from large long-term studies to support these recommendations [33] . Both benign and malignant incidental adrenal masses may be noted to have enlarged at follow-up. Libè et al. [40] found that 6% of incidental adrenal masses show growth at 1-year follow-up, whereas 14% show growth at 2 years and 29% exhibit growth at 5 years, although that study recorded incidental adrenal mass size without mentioning imaging characteristics. A multicenter study of adrenal adenomas with a follow-up of 5 years or more found that adenoma growth of 1 cm or more occurred in 8.3% of patients and that growth greater than 2.5 cm occurred in 2.4% of patients [43] .
The justification for follow-up imaging of AIs with benign characteristics has been patient and physician reassurance through the early detection of growth of malignant masses [5, 33, 37, 38] . Opposing opinions regarding follow-up imaging have been expressed because of the rarity of detection of malignancy on follow-up studies and because of the associated cost and radiation risks [6, 38, 48] . The chance of detecting malignancy during follow-up of benign nonfunctional AIs (0.2% over 2 years) is similar to the predicted risk of the ionizing radiation produced by follow-up CT scans inducing a fatal cancer [38] . Other than the steps required to categorize incidental nodules as benign or malignant, the ACR guidelines do not recommend long-term imaging follow-up. A 1-year follow-up examination could be considered for AIs with benign (but nondiagnostic) imaging features in patients who have no history of malignancy and who have not undergone previous imaging. This guidance is particularly helpful in the common situation of detecting a small (< 4 cm) AI on a CECT examination performed for a patient without known malignancy.
The fourth objective of these guidelines is the biochemical evaluation and follow-up of AIs. AIs may develop cortisol hyperfunction over time, even if they are not hormonally active at the time of the initial evaluation. The risk of a mass larger than 2.4 cm becoming hormonally active is 17% at 1 year, 29% at 2 years, and 47% at 5 years [47] . There is good agreement among the clinical recommendations that individuals with benign nonfunctioning AIs measuring greater than 2.4 cm should obtain annual hormonal testing for Cushing syndrome for 4 years [4, 5, 33] . Other than consideration of initial biochemical evaluation of patients with signs or symptoms of adrenal hyperfunction, the ACR guidelines do not recommend long-term follow-up of hormonal function.
Revised Recommendations
The immediate imaging workup for AI should follow the guidelines proposed by the ACR [2] . Myelolipomas and simple cysts require no additional workup or follow-up imaging. Benign adenomas are characterized by unenhanced CT attenuation of less than 10 HU, signal loss on opposed-phase chemical selective MRI, stable size for more than 1 year (compared with size noted on previous imaging studies, if available), and size less than 4 cm plus imaging features indicating benign status (e.g., homogeneous, low density, and smooth margins) in a patient without a history of cancer [11-14, 49, 50] . If these criteria are not met, CECT with 15-minute delayed imaging is recommended to calculate contrast washout.
For patients with known malignancy, FDG PET or biopsy (performed after exclusion of pheochromocytoma on the basis of results of biochemical analysis) may be helpful in discriminating metastatic disease from benign masses. There is general agreement that surgery should be considered for lesions larger than 4 cm (rather than the previously reported size of 6 cm [5] ), which lack the characteristics of benign tumors [33, 36, 37] . Conservative management may be appropriate for patients with limited life expectancy [33] .
Rather than supplant the recommendations of the ACR Incidental Findings Committee Garrett et al. [2, 3] , we propose a modification of the existing guidelines with respect to biochemical evaluation and percutaneous biopsy (Fig. 8) .
Most AIs are not hormonally active. However, subclinical hyperfunction has been associated with an increased risk of cardiovascular events, obesity, hypertension, osteoporosis, and diabetes. Performing biopsy or surgery for patients with pheochromocytoma, including subclinical pheochromocytoma, without adequate evaluation and patient preparation may result in a hypertensive crisis. Therefore, all incidentally detected adrenal masses 1 cm or larger should undergo biochemical evaluation, unless the imaging features are diagnostic of a nonfunctional process (e.g., myelolipoma or cyst). In addition to the initial biochemical evaluation, an additional yearly follow-up examination to evaluate cortisol secretion should be performed for masses larger than 2.4 cm or if such an examination is clinically indicated on the basis of new signs or symptoms.
Despite clinical recommendations for prolonged imaging follow-up of adrenal nodules, few data support this practice for a benign nodule without hormonal activity. Biopsy should be limited to patients with a known malignancy for whom AI status remains indeterminate after the imaging options are exhausted, and the knowledge of adrenal metastasis will influence clinical management.
Sample Dictations
Many referring physicians may be unaware of the appropriate imaging and biochemical workup for patients presenting with an AI [10] . The recommendations of the reporting radiologist influence the subsequent adrenal imaging and hormonal workup coordinated by the referring physician [51] . Therefore, we think that the burden is on the radiologist to inform referring physicians of the appropriate recommendations. It would be prudent for diagnostic radiologists to discuss the various recommendations with their endocrinology colleagues to develop a local consensus. Four standard dictations have been developed at our institution to address the most common scenarios that are encountered when an AI is detected (Table 2) .
Conclusion
The incidental adrenal mass remains a common challenge for radiologists and referring physicians. A complex array of imaging techniques is available to characterize adrenal masses as benign or malignant. Still, even benign adrenal masses may be clinically relevant if they are hormonally active. Significant differences exist among the algorithms developed for radiologic imaging and endocrine evaluation of AIs. This article provides a brief overview of adrenal imaging, emphasizes key differences between the guidelines developed to evaluate AIs, and proposes an algorithm that attempts to bridge these guidelines. Radiologists play a key role in characterizing adrenal masses as benign or malignant and in recommending further imaging and biochemical evaluation for AIs. Until greater agreement is reached in the medical community, it would be prudent for diagnostic radiologists to discuss these topics with their endocrinology colleagues to develop a local consensus.
